Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]

Livongo Health21 enrolled

Overview

The Livongo-Insulia Study App Pilot Study (LISA Pilot) is a 3-month, prospective, interventional study. The purpose of this pilot study is to evaluate the feasibility of using the Livongo-Insulia Study App for individuals with type 2 diabetes using basal insulin. This will be assessed by measuring the impact of the Livongo-Insulia Study App on glycemic control for these individuals.

Study Type

INTERVENTIONAL

Allocation

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Type 2 Diabetes Treated With Insulin

Interventions

Livongo-Insulia Study AppDEVICE

Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Lives in the U.S. * Able to speak, read and write in English * Diagnosed with type 2 diabetes * Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo, Basaglar, Tresiba U-100) and taking 1 injection per day * Takes a daily dose ≤ 0.75 units/kg * Estimated A1c ≥ 8% (based on existing Livongo data) * Has been enrolled in Livongo for at least 12 weeks * Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS 8 or newer) * Willing to complete study questionnaires * Willing to complete at-home A1c kits * Willing to check before breakfast blood glucose at least once per day Exclusion Criteria: * Diagnosis of type 1 diabetes * Currently using a long-acting basal insulin analog that is not supported by Insulia * Currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins * Currently pregnant or planning pregnancy

Locations (1)

Livongo

Mountain View, California, United States

Outcomes

Primary Outcomes

Change in A1c

Change in A1c from baseline to 12 weeks

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.